Problem

Talc addresses the costly, slow process of extracting usable information from messy electronic health records and narrative medical notes. Hospitals and medical researchers may need to identify events, clinical metrics, or niche findings across large chart populations, but Talc’s site says that doing this manually takes hundreds of hours and a small army of staff. The clearest use case is turning unstructured notes into structured data for applications such as patient-safety measurement or medical research.

Product / Service

Talc is an access-controlled, LLM-powered medical-abstraction platform. Users define their own abstraction rubric or query, and Talc applies those rules line by line across thousands of notes. The system extracts events, metrics, and insights, cites the source material, and flags ambiguous cases for human review, combining the speed of automation with an audit and quality-control workflow. The company promises initial results in minutes and completed jobs in hours, rather than the hundreds of manual hours its target customers would otherwise spend.

Market

Talc competes in AI-enabled clinical data abstraction and unstructured EHR-data extraction, serving hospitals, research centers, and other healthcare-data teams. Its positioning overlaps with products such as Brim Analytics, which automates chart abstraction from electronic medical records, Reveleer’s AI chart-abstraction offering, and Abstractive Health’s medical-record summaries and clinical question answering. Talc’s YC profile labels it “Event extraction for Medical Researchers” and says it helps hospitals pull events and data from messy EHRs, while the current website emphasizes medical abstraction at scale.

The company appears to be early-stage but has several public traction signals: it is an active Y Combinator Summer 2023 company, was founded by Max Kerr and Matt Lee, and is listed with a three-person Seattle team. Talc’s homepage says it is trusted by enterprises and research centers, and PitchBook reports $1.5 million raised from Y Combinator, Pioneer Fund, and Apertu Capital. The available evidence does not disclose revenue or establish that Talc is definitively pre-revenue; the public site instead directs prospects to request access, so its commercial scale remains unclear.